Results 161 to 170 of about 399,504 (355)

Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan [PDF]

, 2018
Afia Muhammad Akram, Humera Kausar, Asma Chaudhary, Ahmad Mukhtar Khalid, Muhammad Mudassar Shahzad, Muhammad Akhtar, Muhammad Farooq Sabar, Nadia Sajid, Nawaf Al Anazi, Aamir Aleem, Zafar Iqbal   +10 more
openalex   +1 more source

Mechanisms of Resistance to Cancer Immunotherapy: A Host–Tumor Interaction Perspective; A Review Article

Cancer Nexus, EarlyView.
Mechanisms of resistance to cancer immunotherapy from a host–tumor interaction perspective. The central tumor cell is protected by multiple resistance mechanisms, including genetic mutations, epigenetic modifications, and metabolic alterations. The immunosuppressive tumor microenvironment features myeloid‐derived suppressor cells (MDSCs), regulatory T ...
Mohammed Elmujtba Adam Essa, Hamid Noori, Abdelkareem A. Ahmed   +2 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) [PDF]

, 2021
Andreas Neubauer, Johannes Johow, Elisabeth Mack, Andreas Burchert, Damaris Meyn, Andrea Kadlubiec, Iuliu Torje, Hinnerk Wulf, Claus Vogelmeier, Joachim Hoyer, Chrysanthi Skevaki, Ralf M. Muellenbach, Christian Keller, Carmen Schade‐Brittinger, Caroline Rolfes, Thomas Wiesmann   +15 more
openalex   +1 more source

Advancing therapeutic frontiers: a pipeline of novel drugs for UC management

Frontiers in Gastroenterology
Ulcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors
Luisa Bertin, Alessandro Massano, Carlo Redavid, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Andrea Buda, Fabiana Zingone, Brigida Barberio, Edoardo Vincenzo Savarino   +9 more
doaj   +1 more source

Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor [PDF]

, 2007
Akihiro Muto, Mayumi Hori, Yosuke Sasaki, Akari Saitoh, Iho Yasuda, Tadahito Maekawa, Tomoe Uchida, Keiko Asakura, Tomonori Nakazato, Toshio Kaneda, Masahiro Kizaki, Yasuo Ikeda, Tadashi Yoshida   +12 more
openalex   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

Experimental Pharmacological Management of Psoriasis

Journal of Experimental Pharmacology, 2021
Elena Campione,1 Terenzio Cosio,1 Monia Di Prete,2 Caterina Lanna,1 Annunziata Dattola,1 Luca Bianchi1 1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2Anatomic Pathology, University of Rome Tor ...
Campione E, Cosio T, Di Prete M, Lanna C, Dattola A, Bianchi L   +5 more
doaj  

Supplementary Table 1, Figures 1 - 2 from The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers <i>In Vitro</i> and <i>In Vivo</i>

, 2023
Jih‐Hsiang Lee, Kang‐Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng‐Tzu Weng, Yisong Wang, Giuseppe Giaccone   +6 more
openalex   +2 more sources

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source